Sirolimus for active lupus symptoms in adults
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This Phase 2 trial tests sirolimus (a medicine that affects the immune system) to reduce symptoms and disease activity in adults with active systemic lupus erythematosus (SLE). You may be a good fit if your lupus is currently active despite stable standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older.
- Have lupus that meets standard classification criteria (your clinician confirms you have SLE) and a positive ANA blood test at or above 1/80.
- Have been on stable lupus medicines for a set time before screening, such as hydroxychloroquine (up to 400 mg/day), and/or certain other immune medicines, plus a stable steroid dose (up to 20 mg/day prednisone or equivalent).
- Have active lupus disease based on activity scores your doctor measures (at least one organ/system affected and an overall activity score of 6 or higher).
- You must not be pregnant or breastfeeding, and you must not plan pregnancy (or father a child) during the study and for 3 months after the last dose.
- You need recent lab results that are not too low (red blood cells, white blood cells, neutrophils, platelets) and kidney/protein levels must meet limits (no very high protein in urine, and kidney function above 50 mL/min/1.73 m²).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called AZD0120 in adults with lupus that hasn't improved with standard treatments. The goal is to see if it's safe and works well for people with lupus-related organ problems.
This trial tests belimumab to see if it can improve lupus (SLE) disease activity in people who were diagnosed within the last two years. You may be eligible if your lupus is currently mild to moderate and your background lupus medicines are stable.
This trial tests sirolimus, an immune-system-calming medicine, for people with lupus who also have very low platelet counts (ITP). It may help reduce bleeding risk and improve platelet numbers.
This study tests whether the drug sirolimus (Rapamune) is safe and effective for people with antiphospholipid syndrome (APS), a condition that increases blood clot risk. It may offer a new option for those whose current treatment is stable.
This trial tests if sirolimus, a medicine that calms the immune system, can safely raise platelet counts in people with antiphospholipid antibodies and persistently low platelets. It may be an option if other treatments haven't worked or you want a simpler drug plan.
This Phase 2 trial studies whether sirolimus can slow or prevent functional decline (more difficulty with daily activities) in older adults. You may be considered if you’re in the right age range and have no major heart, lung, liver, kidney, or recent bleeding/clotting problems.
Hear when a new Lupus Erythematosus, Systemic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.